Australian Nursing Homes Told: "Reduce Drug Levels"

18 November 1996

A study by the University of Queensland has recommended that drugs administered to nursing home patients can be safely reduced by 11%-15%. The study found that such a reduction would save the community an estimated A$4.5 million ($3.5 million) a year if applied to the country's more than 74,000 nursing home residents.

A University spokesman commented that the main changes in residents' drug therapy during the study were a reduction in sleeping pill and antipsychotic drug use, plus the addition of painkillers, as pain was found to contribute to many secondary problems in the frail elderly.

The Australian government has reacted favorably to the study, and has suggested that clinical pharmacists should be involved in the care of nursing home patients. It also believes that nursing homes should encourage formal processes for clinical pharmacists to review medication use. During the Queensland study, clinical pharmacists advised on unnecessary or inappropriate medication, and suggested alternatives.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight